NYSE - Nasdaq Real Time Price USD

Glaukos Corporation (GKOS)

90.54

+2.30

+(2.61%)

At close: May 8 at 4:00:02 PM EDT

91.00

+0.46

+(0.51%)

After hours: May 8 at 7:32:17 PM EDT

Glaukos First Quarter 2025 Earnings: Beats Expectations

Glaukos ( NYSE:GKOS ) First Quarter 2025 Results Key Financial Results Revenue: US$106.7m (up 25% from 1Q 2024). Net...

Simply Wall St. 6 days ago

GKOS
+2.61%
Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks 7 days ago

GKOS
+2.61%
GKOS Stock Falls Despite Q1 Earnings & Revenue Beat, Margins Decline

Glaukos' first-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern.

Zacks 7 days ago

GKOS
+2.61%
Q1 2025 Glaukos Corp Earnings Call

Q1 2025 Glaukos Corp Earnings Call

Thomson Reuters StreetEvents 7 days ago

GKOS
+2.61%
Glaukos Corp (GKOS) Q1 2025 Earnings Call Highlights: Record Sales and Strategic Growth Amid ...

Glaukos Corp (GKOS) reports a 25% increase in net sales, reaffirming its full-year guidance while navigating market turbulence and competitive pressures.

GuruFocus.com 7 days ago

GKOS
+2.61%
Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates

Glaukos (GKOS) delivered earnings and revenue surprises of 33.33% and 3.84%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 8 days ago

GKOS
+2.61%

MTD
Glaukos: Q1 Earnings Snapshot

GKOS) on Wednesday reported a loss of $18.1 million in its first quarter. On a per-share basis, the Aliso Viejo, California-based company said it had a loss of 32 cents. Losses, adjusted for amortization costs, came to 22 cents per share.

Associated Press Finance 8 days ago

GKOS
+2.61%
Glaukos Announces First Quarter 2025 Financial Results

ALISO VIEJO, Calif., April 30, 2025--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2025. Key highlights include:

Business Wire 8 days ago

GKOS
+2.61%
Earnings Preview: Mettler-Toledo (MTD) Q1 Earnings Expected to Decline

Mettler-Toledo (MTD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 14 days ago

MTD

GKOS
+2.61%
Glaukos (GKOS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 15 days ago

GKOS
+2.61%
$Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting$

Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

ALISO VIEJO, Calif., April 23, 2025--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held April 25-28, 2025 in Los Angeles, CA. Glaukos will be exhibiting onsite at booth #2227.

Business Wire 15 days ago

GKOS
+2.61%
Glaukos Announces the Release of its 2024 Sustainability Report

ALISO VIEJO, Calif., April 16, 2025--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2024 Sustainability Report. The report highlights the company’s continued commitment and progress on its key corporate sustainability initiatives. The Sustainability Report can be found on the company’s website here.

Business Wire 22 days ago

GKOS
+2.61%
Strength Seen in Veracyte (VCYT): Can Its 13.0% Jump Turn into More Strength?

Veracyte (VCYT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks 28 days ago

VCYT

GKOS
+2.61%
Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30

ALISO VIEJO, Calif., April 09, 2025--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2025 financial results after the market close on Wednesday, April 30, 2025. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on April 30, 2025.

Business Wire 29 days ago

GKOS
+2.61%
What Makes Glaukos Corporation (GKOS) a Compelling Stock?

ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The stock market performance in the first quarter of 2025 was volatile, following the initial “animal spirits” post-election rally. The strategy surpassed its benchmark with the support of […]

Insider Monkey 30 days ago

GKOS
+2.61%
The Zacks Analyst Blog Highlights Alcon, Glaukos and Regeneron Pharmaceuticals

Alcon, Glaukos and Regeneron Pharmaceuticals are part of the Zacks top Analyst Blog.

Zacks last month

REGN

ALC.SW

GKOS
+2.61%
3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space

ALC, GKOS and REGN are well-positioned to benefit from the evolving space of cell-based ophthalmic therapy.

Zacks last month

REGN

GKOS
+2.61%
Breakeven On The Horizon For Glaukos Corporation (NYSE:GKOS)

With the business potentially at an important milestone, we thought we'd take a closer look at Glaukos Corporation's...

Simply Wall St. last month

GKOS
+2.61%
Here's Why You Should Retain Glaukos Stock in Your Portfolio

GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.

Zacks last month

GKOS
+2.61%
RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution

ALISO VIEJO, Calif., March 11, 2025--Topcon Healthcare, Inc., RadiusXR, and Glaukos Corporation (NYSE: GKOS) announced a new collaboration and the launch of RadiusXR’s new wearable vision testing platform - Inspire®. This collaboration unites RadiusXR’s innovative visual field platform and Topcon Healthcare’s global leadership in robotic diagnostics and digital healthcare solutions with Glaukos’ commitment to expanding patient access by democratizing the diagnosis of ophthalmic diseases such as

Business Wire last month

GKOS
+2.61%

Performance Overview

Return	GKOS	S&P 500 (^GSPC)
YTD	-39.62%	-3.70%
1-Year	-15.31%	+9.18%
3-Year	+118.96%	+37.36%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Glaukos Corporation (GKOS)

Glaukos First Quarter 2025 Earnings: Beats Expectations

Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

GKOS Stock Falls Despite Q1 Earnings & Revenue Beat, Margins Decline

Q1 2025 Glaukos Corp Earnings Call

Glaukos Corp (GKOS) Q1 2025 Earnings Call Highlights: Record Sales and Strategic Growth Amid ...

Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates

Glaukos: Q1 Earnings Snapshot

Glaukos Announces First Quarter 2025 Financial Results

Earnings Preview: Mettler-Toledo (MTD) Q1 Earnings Expected to Decline

Glaukos (GKOS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Glaukos Announces the Release of its 2024 Sustainability Report

Strength Seen in Veracyte (VCYT): Can Its 13.0% Jump Turn into More Strength?

Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30

What Makes Glaukos Corporation (GKOS) a Compelling Stock?

The Zacks Analyst Blog Highlights Alcon, Glaukos and Regeneron Pharmaceuticals

3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space

Breakeven On The Horizon For Glaukos Corporation (NYSE:GKOS)

Here's Why You Should Retain Glaukos Stock in Your Portfolio

RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution

Performance Overview